Haisco Gets NMPA Clinical Trial Approval for Migraine Drug HSK51155
Haisco announced on August 6, 2026, that it recently received a Drug Clinical Trial Approval Notice issued by the National Medical Products Administration (NMPA) for HSK51155 tablets. The drug is an oral small-molecule analgesic independently developed by the company with independent intellectual property rights, and is clinically intended for the treatment of migraine.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is positive for Pharmaceuticals, with intensity 40/100 and 70% confidence over a medium term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.